Arvinas (ARVN) vs Indaptus Therapeutics (INDP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Indaptus Therapeutics (INDP) has outperformed Arvinas (ARVN) over the past year, gaining 52.4% versus a loss of 43.9%. Over five years, ARVN leads with a -91.8% price change compared with -98.3% for INDP. Indaptus Therapeutics is the larger company by market cap ($433.2 million vs $423.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARVN | INDP |
|---|---|---|
| Share price | $6.46 | $2.82 |
| Market cap | $423.03M | $433.16M |
| 1-day change | -4.15% | -9.90% |
| YTD return | -45.53% | -3.09% |
| 1-year return | -43.92% | +52.43% |
| 5-year return | -91.75% | -98.26% |
| EPS (TTM) | $-0.08 | $-3.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $262.60M | — |
| Revenue growth (YoY) | -0.30% | — |
| Net income (latest FY) | $-80.80M | $-20.85M |
| Operating margin | -45.13% | — |
| Net margin | -30.77% | — |
| 52-week high | $14.51 | $5.96 |
| 52-week low | $6.33 | $0.92 |
| Distance from 52-week high | -55.48% | -52.68% |
| Analyst consensus | buy | — |
| Avg. price target upside | +116.72% | — |
| Average volume | 848.52K | 712.87K |
| Shares outstanding | 65.49M | 153.60M |
| Employees | 246 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INDP has outperformed ARVN by 96.4 percentage points over the past year.
About Arvinas
ARVN stock →Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Health Care · Biotechnology: Pharmaceutical Preparations · 246 employees
About Indaptus Therapeutics
INDP stock →Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
ARVN vs INDP FAQ
Which is bigger, Arvinas or Indaptus Therapeutics?
Indaptus Therapeutics (INDP) is larger, with a market capitalization of $433.16M compared with $423.03M for Arvinas (ARVN).
Which stock has performed better over the past year, ARVN or INDP?
INDP returned +52.43% over the past 12 months, compared with -43.92% for ARVN (price return, excluding dividends). Past performance does not predict future results.
Are Arvinas and Indaptus Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.